CLIA Certified Lab

COVID-19 PCR TEST

Rapid antigen and RT-PCR tests differ in their analytic sensitivity. Typically, the sensitivity of antigen tests is 30% to 40% lower than for RT-PCR, depending on whether tested subjects were symptomatic or asymptomatic [reference]

However, lower sensitivity has both disadvantages and benefits.

The primary disadvantage is a risk of falsely negative results in people with low viral loads who may be early in their infection, and who go on to spread it to others in subsequent days. In practice, this subpopulation represents just a small fraction of those tested, and risk can be mitigated through serial testing algorithms. There is also a slightly elevated rate of false positives relative to molecular tests, though the rate is dependent on the prevalence of disease and the proportion of people who are symptomatic. A paper published in Lancet, Infectious Diseases noted that for many commonly-used rapid antigen tests, the negative predictive value (e.g., the likelihood someone with a negative test is truly negative for infection) is greater than 98%. [reference]

A major advantage of these assays is the lower likelihood of detecting residual viral nucleic acid left over from a remote infection in recovered individual. This reduces the chance of unnecessary initiation of isolation and quarantine precautions and subsequent rounds of testing.

Rapid antigen tests are subject to the same considerations as the PCR tests with respect to factors that affect clinical sensitivity. These include the quality of sampling and the timing of testing relative to the onset of infection. The CDC advises that rapid antigen tests can have a lower performance in the asymptomatic population, which may be related to the lower levels of virus in this group relative to those with symptoms, rather than characteristics of the tests themselves [reference]

Nucleic Acid Amplification Tests (NAATs) such as RT-PCR for SARS-CoV-2 are designed to detect viral RNA. A positive result is highly specific for the presence of COVID-19 viral nucleic acid.  However, it is very important here to note that a positive RT-PCR test does not differentiate between viable and nonviable virus. Thus, a positive test does not necessarily indicate that a person is infectious and requires isolation.

A variety of gene targets are available across different assays, including the envelope gene, the nucleocapsid gene, the ORF1ab gene, and the spike gene. Most assays are designed to detect two or more gene targets. The FDA maintains an up-to-date list of assays with emergency use authorization. [reference]

The RT-PCR’s clinical sensitivity is affected by the assay’s limit of detection, the time since infection began, and sample type. Because patients with symptoms tend to present earlier in their infection course, there is increased test sensitivity in symptomatic people relative to asymptomatic people. Traditionally the nasopharynx has been the preferred body site for sampling, but given patient discomfort and the need for serial testing, many hospitals, and public health programs now use anterior nares or saliva as the primary sampling type.

The Infectious Diseases Society of America as issued guidelines that recommend NAAT (including RT-PCR) for:  

All symptomatic individuals suspected of having COVID-19;

Asymptomatic individuals with known or suspected contact with a COVID-19 case;

Asymptomatic individuals when the results will impact isolation/quarantine/personal protective equipment usage decisions, dictate eligibility for surgery, or inform the administration of immunosuppressive therapy.

NAAT testing in symptomatic people, even when clinical suspicion is low;

NAAT testing in asymptomatic individuals with known or suspected exposure to COVID-19, those requiring hospitalization when community prevalence is high or prior to solid organ or stem cell transplantation and time-sensitive surgeries;

Repeating viral RNA testing when the initial test is negative in symptomatic individuals with intermediate or high clinical suspicion;

Specimen collection from the nasopharynx, mid-turbinate, anterior nares, or combined nasal/oropharyngeal over oropharynx alone.

The COVID-19 antibody test looks for IgM and IgG antibodies in the blood to determine if your body has already responded to the novel coronavirus or if you have not developed antibodies (you have a higher risk of getting the virus if you do not have antibodies).

Nasal swab: Quest Diagnostics performs the nasal swab RT-PCR.  Quest reports that the concentration of SARS-CoV-2 RNA that was successfully detected with at least a 95% detection rate was calculated as 136 copies/mL.  It is important to note that timing and adequate sampling determine this test’s sensitivity.  Recent data show that RNA positive rates peaked in upper respiratory tract specimens at 7–10 days after symptom onset and then steadily declined after that.  Sensitivity also depends on an adequate sample being collected and the disease having advanced enough to have a higher number of viral RNA copies.

IgG antibodies:    We offer the Roche Elecsys Anti-SARS-CoV-2 igG Total Antibody test. Roche reports an overall test specificity of 99.81 % (99.65 – 99.91 %) and a sensitivity in patients 14 days after PCR confirmation to be 100% (88.1 – 100 %).

Both, Quest Diagnostics and Roche offer testing in accordance with the FDA Emergency Use Authorization Guidance.

Antibody tests, also known as serology tests, differ from the nasal- and throat-swab tests that can spot a current infection. Instead, these look for signs in the blood that the immune system had fought off an infection in the past.

But there are limits to what antibodies can reveal. With other infectious diseases, antibodies signal a measure of protection against getting sick again. No one knows if that is true of this virus, or, if it is, how long such immunity might last.

A positive test result with the qSARS-CoV-2 IgG/IgM test indicates that antibodies to SARS-CoV-2 were detected, and the patient has potentially been exposed to COVID-19. When IgM antibodies are present, they can indicate that a patient has an active or recent infection with SARS-CoV-2. IgG antibodies develop later following infection, and generally do not begin to appear until 14-21 days after infection. When IgG antibodies are present it, often indicates a past infection but does not exclude recently infected patients who are still contagious, especially if detected with IgM antibodies. 

Since most patients do not know the exact time when they contracted the virus, the combining both IgM and IgG tests provides a much higher test sensitivity and test specificity.

The presence of antibodies and immunity

It is unknown how long IgM or IgG antibodies to SARS-CoV-2 will remain present in the body after infection and if they confer immunity to infection.

If you think you might have been exposed to the COVID-19, please schedule your appointment immediately.

TESTING IS FREE IF YOU ARE A US RESIDENT AND WE ACCEPT YOUR INSURANCE:

A). You have health insurance AND and its accepted by us: Your insurance will cover all costs of evaluation & COVID testing. We accept a wide variety of insurance plans for covid testing.

B). You do not have health insurance – The CARES act will NOT COVER the evaluation & coronavirus testing costs for anyone without insurance as of March 21, 2022.

IF A OR B DO NOT APPLY TO YOU:

• AND YOUR INSURANCE COVERAGE IS BY MEDICAID, PLEASE CLICK HERE FOR PRICING.

• AND YOU DO NOT HAVE INSURANCE AND DO NOT HAVE A U.S. SSN# PLEASE CLICK HERE FOR PRICING.

One potential use of COVID antibody tests is to measure the extent of the pandemic at the population level. Our understanding of the disease and its projected impact in the US is weakened by our inability to monitor its spread among people with either mild symptoms or none at all.

Another use is to measure the progress of individual infection. Antibody tests quantify the number of immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies in the blood. The presence of more IgM antibodies, which are the first to appear and mobilize against an invading organism, indicates more recent exposure to the virus. It is through this result that an asymptomatic carrier of the virus could be identified—a feature of no small importance, since “silent carriers” have played a major role in transmission.

More IgG antibodies, which are virus specific and produced in later stages of infection, would lead a person to test positive for immunity, implying recovery. This unfortunately doesn’t guarantee full protection. The test won’t reveal how neutralizing, or how potent, these IgG antibodies are; nor can it determine how long they will last. With certain families of coronaviruses, including the beta coronavirus family that includes SARS-CoV-2, reinfection has been found to occur, and for now it remains a possibility.

Successful deployment of antibody tests depends on their “sensitivity and specificity.” Sensitivity prevents false negatives, since a more sensitive test is more likely to actually detect it. Specificity, on the other hand, prevents false positives, since a less specific test may pick up on antibodies against a virus other than SARs-CoV-2.

It would take a concerted effort, but in the United States we have the infrastructure and manpower it takes to conduct rapid antibody tests quickly, cheaply, and at a massive scale. The small European country of Andorra has plans to give antibody tests to its entire population. Compared to other resource rich nations, we’ve failed to answer the WHO director general’s call to “test, test, test.” That can change—but only if we act now, and act fast.